HBK Investments’s Alder Biopharmaceuticals ALDR Stock Holding History

HBK Investments’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-11,500	Closed	-$182K	–	1430
2018 Q2	$182K	Buy	+11,500	New	+$175K	﹤0.01%	969
2016 Q2	–	Sell	-11,500	Closed	-$282K	–	1150
2016 Q1	$282K	Buy	+11,500	New	+$266K	﹤0.01%	842
2015 Q4	–	Sell	-98,700	Closed	-$3.23M	–	1190
2015 Q3	$3.23M	Buy	+98,700	New	+$4.2M	0.03%	319

Other funds holding ALDR

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HBK Investments's ALDR Position: Q3 2018 in Review

HBK Investments sold out of Alder Biopharmaceuticals (ALDR) in Q3 2018, closing a stake of 11,500 shares — an estimated $182K sold.

HBK Investments first reported a position in ALDR in Q3 2015 and held it in 3 quarters. The position peaked at $3.23M in Q3 2015. 127 funds tracked by Wall St. Rank hold ALDR as of Q3 2018.

HBK Investments reported no remaining Alder Biopharmaceuticals position as of Q3 2018 after selling out during the quarter.
HBK Investments sold 11,500 Alder Biopharmaceuticals shares in Q3 2018, an estimated $182K.
HBK Investments first reported a position in Alder Biopharmaceuticals in Q3 2015 and held it in 3 quarters.
HBK Investments's Alder Biopharmaceuticals position peaked at $3.23M in Q3 2015.
127 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2018.

Based on HBK Investments's 13F filing for Q3 2018, filed 14 Nov 2018.